by Steven Grossman | Aug 28, 2025 | Short Takes and Updates
For much of the past 20 years, my primary professional responsibility has been to impress upon lawmakers, the media, and stakeholders that FDA’s value far exceeds its budget. Sometimes, I would emphasize the economics — FDA oversees goods and services that total...
by Steven Grossman | Aug 25, 2025 | Uncategorized
———This week’s questions:Why has CDRH seemed uniquely untouched by this year’s upheaval at the FDA? How does the WSJ editorial on drug approvals (here) relate to your late July article (here) calling for a National Agenda for Advancing Therapies for...
by Steven Grossman | Aug 20, 2025 | Short Takes and Updates
(An earlier version of this column appeared in Food Safety News at https://bit.ly/417cLOJ) —————Preamble: The Make America Healthy Again (MAHA) movement has sparked an overdue examination of how to improve the health of Americans,...
by Steven Grossman | Aug 18, 2025 | Uncategorized
Dear FDA Matters subscribers Q&A Monday is a subscriber-first feature of FDA Matters. It is on the record, so subscribers (including reporters) can use and circulate the Q&A immediately upon receipt.Subscribers are encouraged to submit questions about any...
by Steven Grossman | Aug 12, 2025 | Short Takes and Updates
FDA Matters doesn’t cover the news….we provide analysis of what’s behind the newsThe goal of FDA Matters is to analyze FDA policy and regulatory issues and advocate for a more effective, more efficient, and fairer FDA. In support of the agency, I...
